In its biotechnology industry India is a proud contributor of more than $700 million in annual revenues. With a growth of 40% over the past year, she is second only to United States in the total number of FDA-approved drug manufacturing plants. The various factors accounting for India’s blossoming biotechnology industry are skilled laborers, low costs, new patent protections and a pool of patients ready for clinical trials. Indian companies are ready learners with its good number of educated scientists.



India therefore stands as a good destination for manufacturers and marketers. Several European companies and US are prompted to set up their units in this country. They also contemplate on forming contracts with Indian firms for drug-development research, clinical trials and research-data analysis.

According to industry experts India is to soon become a powerful player in global biotechnology and all by its own merit and may even pose a threat to other nations. To further support this situation, India is already acquiescing to World Trade Organization (WTO) patent protections. This would enable Indian firms to find a base in developed markets of US and Europe, which will further encourage companies to enhance their R&D with the objective of patenting their own high-end products.

In its market research report, “Indian Biotechnology Market Outlook (2006)" RNCOS specialists believe that although Indian biotechnology has just started to develop and holds only 1% of the global biotechnology market, it is poised for a favorable growth with an expected world market share of 10% over the next five years.

The report gives a fair picture of the future Indian biotech market, the initiatives and policies of central and state governments covering all segments of the market. Having made an intensive SWOT analysis the report analyzes the sector in terms of size, demand, and foreign and domestic markets for 2005 while making forecasts till 2010.

Finally the report lists company profiles of 20 major companies in the biotech industry including Shantha Biotechnics, Biocon, Bharat Biotech, Wockhardt, Serum Institute of India, Zydus Cadila, and Aventis Pharma.

The report can make useful reading for this sector’s technicians, manufacturers and researchers.

To purchase your copy: http://www.rncos.com/Report/Biotech14.htm

For more information please visit www.rncos.com